Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review

2021 ◽  
Vol 158 ◽  
pp. 47-62
Author(s):  
Mathieu Larroquette ◽  
Charlotte Domblides ◽  
Félix Lefort ◽  
Matthieu Lasserre ◽  
Amandine Quivy ◽  
...  
2021 ◽  
pp. 1-7
Author(s):  
Laura Haik ◽  
Aurore Gonthier ◽  
Amandine Quivy ◽  
Marine Gross-goupil ◽  
Remi Veillon ◽  
...  

2020 ◽  
Vol 31 ◽  
pp. S714
Author(s):  
M. Maugeais ◽  
J. Peron ◽  
S. Dalle ◽  
M. Duruisseaux ◽  
P. Corbaux ◽  
...  

2019 ◽  
Vol 30 ◽  
pp. v519-v520
Author(s):  
F J Ros Montana ◽  
I. Matos ◽  
G. Vilacampa ◽  
A. Azaro ◽  
J. Martin-Liberal ◽  
...  

2019 ◽  
Vol 30 ◽  
pp. v524-v525
Author(s):  
S. Mebarki ◽  
M. Gisselbrecht ◽  
E. Fabre ◽  
E. Mercadier ◽  
S. Oudard ◽  
...  

Life ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1400
Author(s):  
Alejandro Olivares-Hernández ◽  
Luis Figuero-Pérez ◽  
José Pablo Miramontes-González ◽  
Álvaro López-Gutiérrez ◽  
Rogelio González-Sarmiento ◽  
...  

The relationship between viral infections and cancer is well known and has been established for decades. Multiple tumours are generated from alterations secondary to viral infections 2 resulting from a dysregulation of the immune system in many cases. Certain causal relationships, such as that between the Epstein–Barr virus (EBV) in nasopharyngeal cancer or hepatitis C and B viruses in hepatocarcinoma, have been clearly established, and their implications for the prognosis and treatment of solid tumours are currently unknown. Multiple studies have evaluated the role that these infections may have in the treatment of solid tumours using immunotherapy. A possible relationship between viral infections and an increased response to immune checkpoint inhibitors (ICIs) has been established at a theoretical level in solid neoplasms, such as EBV-positive cavum cancer and human papillomavirus (HPV)-positive and oropharyngeal cancer. These could yield a greater response associated with the activation of the immune system secondary to viral infection, the consequence of which is an increase in survival in these patients. That is why the objective of this review is to assess the different studies or clinical trials carried out in patients with solid tumours secondary to viral infections and their relationship to the response to ICIs.


2020 ◽  
pp. clincanres.1163.2020 ◽  
Author(s):  
Alexandra Pender ◽  
Emma Titmuss ◽  
Erin D Pleasance ◽  
Kevin Y Fan ◽  
Hillary Pearson ◽  
...  

ESMO Open ◽  
2020 ◽  
Vol 5 (2) ◽  
pp. e000653
Author(s):  
Yutaka Fujiwara ◽  
Aya Kuchiba ◽  
Takafumi Koyama ◽  
Ryunosuke Machida ◽  
Akihiko Shimomura ◽  
...  

BackgroundPatients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell activation induced by immune checkpoint inhibitors (ICIs) relates to infection.MethodsWe retrospectively examined infection risk in patients with cancer treated with investigational agents in a phase I study. The investigational agents were classified into four groups: CTA, phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin inhibitor (PAM), molecular targeted agent (MTA) and ICI. All infection-related adverse events (AEs) during treatment were recorded. We compared the CTA, PAM and ICI with MTA, because MTA are already considered low risk and were used in the largest number of patients.ResultsA total of 641 patients were enrolled: 35 CTAs (5.5%), 61 PAMs (9.5%), 445 MTAs (69.4%) and 100 ICIs (15.6%). Among all patients, 132 (20.6%) experienced infection-related AEs and 46 (7.2%) developed 50 ≥grade 3 infection-related AEs. In any infection-related AEs, the ORs compared with MTAs were 2.19 (95% CI 1.03 to 4.66) for CTAs, 3.55 (95% CI 2.02 to 6.24) for PAMs and 1.05 (95% CI 0.60 to 1.85) for ICIs, respectively. In time to the first infection-related AE analysis, the risks for any infection-related AE from CTAs and PAMs were higher than those from MTAs (HR 1.84 (95% CI 0.82 to 4.11); p=0.05 and 3.96 (95% CI 2.18 to 7.22); p<0.001). The risk from ICIs was not significantly different from that of MTAs (HR 0.71 (95% CI 0.46 to 1.10); p=0.19).ConclusionOur results validate that PAMs and CTAs carry a higher infection risk in patients with advanced solid tumours compared with MTAs. We suggest that the infection risk of ICIs is a similar infection risk to MTAs.


2019 ◽  
Vol 30 ◽  
pp. v521-v522
Author(s):  
L. Ghiglione ◽  
C Cabrera Galvez ◽  
O. Reig ◽  
A. Soler-Perromat ◽  
J.C. Soler-Perromat ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document